

UNITED STATES DEPARTMENT OF COMMERCS Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

FILING DATE ATTORNEY DOCKET NO. APPLICATION NO. **FIRST NAMED INVENTOR** 09/423,035 01/13/00 JOYCE TSRI463.4 **EXAMINER** HM22/1001 THE SCRIPPS RESEARCH INSTITUTE LACOURCIERE,K 10550 NORTH TORREY PINES ROAD **ART UNIT** PAPER NUMBER MAIL DROP TEC 8 LA JOLLA CA 92037 1635 DATE WAILED: 10/01/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No.	Applicant(s)
Office Action Summary	09/423,035	JOYCE ET AL.
	Examiner	Art Unit
The MAILING DATE of this communication appea	Karen A. Lacourciere	1635
Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status		
1) Responsive to communication(s) filed on		
2a) ☐ This action is FINAL. 2b) ☑ This	action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
4)⊠ Claim(s) <u>1-46</u> is/are pending in the application.		
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) <u>1-46</u> are subject to restriction and/or election requirement.		
Application Papers		
9) The specification is objected to by the Examiner.		
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) □ approved b) □ disapproved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.		
12) ☐ The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No.		
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.		
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).		
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/ownships analyst		
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	ry (PTO-413) Paper No(s)

Application/Control Number: 09/423,035

Art Unit: 1635

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372. 1.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-22, and 25-46, drawn to a catalytic DNA molecule, a method of making said molecule and a method of using said molecule.

Group II, claim(s) 23, drawn to a composition comprising a population of two or more catalytic DNA molecules targeted to different sites on a substrate.

Group III, claim(s) 24, drawn to a composition comprising a population of two or more catalytic DNA molecules targeted to different substrates.

The subject matter claimed by claim 35 is unclear, as it recites a method which does not have antecedent basis. Claim 35 is dependent on claim 7 and has been grouped with Group I, which includes the claim which claim 35 is dependent upon.

Page 2

Application/Control Number: 09/423,035 Page 3

Art Unit: 1635

- 2. The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
- 3. An application is considered to have unity of invention if the claims are drawn to a product, a process specially adapted for the manufacture of the said product, and a process of use of the said product (see MPEP 1850, 37 CFR 1.475). In the instant application, multiple products have been claimed and, therefore, unity of invention is lacking. Group I is drawn to the first product, a catalytic DNA molecule targeted to a single site in a single substrate, and a method of manufacture and a process of use of said product. The product of Group I differs from the products of each of Groups II and III that the products of each of Groups II and III are drawn to a population of DNA molecules, which target multiple sites. The products of Group II and Group III differ from each other in that the product of Group II targets multiple sites within a single substrate, whereas the product of Group III targets multiple substrates.
- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

Application/Control Number: 09/423,035

Page 4

Art Unit: 1635

named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen A. Lacourciere whose telephone number is (703) 308-7523.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached at (703) 308-0447. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Karen A. Lacourciere

September 27, 2001

PRIMARY EXAMINER